Inhibition of gastric acid secretion in the dog by the H$_2$-receptor antagonists, ranitidine, cimetidine, and metiamide

M J DALY, J M HUMPHRAY, AND R STABLES

From the Department of Pharmacology, Glaxo Group Research (Ware Division), Ware, Herts

SUMMARY The new H$_2$-receptor antagonist, ranitidine, has been compared with cimetidine and metiamide as an inhibitor of gastric acid secretion in the dog. All three compounds were effective both intravenously or by mouth in inhibiting secretion induced by histamine, pentagastrin, or bethanechol. This inhibition was mainly attributable to a reduction in the volume of secretion, although there was also a significant reduction in the concentration of acid secreted. Metiamide was slightly less active than cimetidine, but ranitidine was four to nine times more potent than cimetidine, depending on the secretagogue used. The antisecretory activity of ranitidine does not result from a limitation in blood flow to the gastric mucosa.

It is now well established that the histamine H$_2$-receptor antagonists metiamide and cimetidine inhibit gastric acid secretion in the dog$^{1,2}$ and in man.$^{3,4}$ Furthermore, cimetidine has proved to be highly effective in the treatment of duodenal ulcer.$^5$ Both metiamide and cimetidine contain an imidazole ring which has been claimed to be an important feature for H$_2$-receptor antagonist activity.$^6$ However, a novel compound, ranitidine (AH 19065) has recently been described$^7$ which lacks an imidazole ring (see Fig. 1), but possesses both potent H$_2$-receptor antagonist and gastric antisecretory activity.

The purpose of the present investigation was to compare the new H$_2$-receptor antagonist ranitidine with metiamide and cimetidine as inhibitors of gastric acid secretion in the dog. The effects of the three H$_2$-receptor antagonists have been studied in conscious dogs with Heidenhain pouches during stimulation of gastric acid secretion by three different secretagogues—histamine, pentagastrin and bethanechol.

Methods

Eight male beagles (13–19 kg) with well-established Heidenhain pouches were used, following the method previously described by Daly and Stables.$^8$ Histamine, pentagastrin, or bethanechol was infused intravenously at a dose known to produce a 50% maximal secretory response in each dog. The doses used were: histamine 0.3–0.5 µg kg$^{-1}$ min$^{-1}$, pentagastrin 1–4 µg kg$^{-1}$ h$^{-1}$ and bethanechol 0.5–1.0 µg kg$^{-1}$ min$^{-1}$. Secretion from the Heidenhain pouch drained into a collection vessel which was changed every 15 minutes; the volume of secretion was measured to the nearest 0.1 ml and acid concentration determined by titration against 0.1 mol/l NaOH to pH7 with a Radiometer TTT2 titration system. Acid output was calculated in µmol H$^+$/min. The secretory stimulant was infused continuously throughout the experiment. Once a plateau of gastric acid secretion had been obtained (less than 15% variation over one hour), a single dose of ranitidine, cimetidine or metiamide was administered as an intravenous bolus or by mouth in a capsule. The three H$_2$-receptor antagonists were tested against each secretory stimulant over the following range of doses; ranitidine (0.03–1.0 mg/kg), cimetidine (0.1–3.0 mg/kg), and metiamide (0.3–3.0 mg/kg).

In some of these experiments the effect of ranitidine on gastric mucosal blood flow was determine
Inhibition of gastric acid secretion in the dog

by the tritiated aniline clearance method of Curwain and Holton, using doses of ranitidine which inhibited gastric acid secretion by approximately 50%.

Results have been calculated as percentage change in the measured parameters by comparison of the test value with the mean of the four values preceding drug administration. The figures quoted refer to change in gastric acid output, unless indicated otherwise. The doses of each H₂-antagonist required to inhibit secretion by 50% (ED₅₀ values) were determined by the method of least squares.

The drugs used were bethanechol chloride (Fabriques de Laires), histamine acid phosphate (BDH), pentagastrin (ICI), cimetidine (Smith, Kline and French Ltd), metiamide (kindly supplied by Dr M E Parsons, Smith Kline and French Ltd), and ranitidine HCl (synthesised at Glaxo Group Research Ltd, Ware). Drug doses have been expressed in terms of the free base throughout this paper.

Results

The effects of ranitidine on histamine-stimulated gastric acid secretion are shown in Fig. 2. Intravenous doses of 0.03-0.30 mg/kg produced dose-related decreases in acid output, peak effect was reached in 15 to 30 minutes after dosing and recovered within four hours at the top dose level. Ranitidine was also markedly effective when given orally at doses of 0.3 and 1.0 mg/kg, peak effects being attained 1½ to two hours after dosing and there was still appreciable antisecretory activity five hours after the oral dose of 1 mg/kg. Results obtained with an oral dose of cimetidine of 3 mg/kg are shown in Fig. 2B. The peak effect of this dose of cimetidine, which was intermediate in effect between ranitidine at 0.3 and 1.0 mg/kg, was reached 1½ to 2½ hours after dosing and complete recovery was observed by 4½ hours. Thus, the duration of action of ranitidine given orally is as long, or longer, than that of cimetidine. Comparison of the

---

**Fig. 2** Effect of ranitidine on histamine-induced gastric acid output after intravenous (A) and oral (B) administration. Values are means from five dogs. Symbols: control O, ranitidine dose (mg/kg) 0.03 ●, 0.10 ▲, 0.30 ■, 1.0 □. Cimetidine at 3.0 mg/kg (△ --- --- △) is also shown in B.

**Fig. 3** Inhibition of histamine-induced gastric acid secretion after intravenous (A) and oral (B) doses of ranitidine ● (solid line), cimetidine ▲ (solid line), and metiamide ■ (broken line). Values are means ± SE from at least five dogs. The lines shown are calculated lines of best fit; there is no significant difference in slope for the three drugs. Asterisks indicate where a value is significantly different from that achieved with the same dose of cimetidine, at *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired t test).
Table 1  Change in histamine-stimulated gastric secretion after oral administration of ranitidine, cimetidine, and metiamide (expressed as a mean percentage reduction ± standard error from pre-dose control value)

<table>
<thead>
<tr>
<th>H2-receptor antagonist and measurement</th>
<th>Dose of antagonist (mg/kg)</th>
<th>0.1</th>
<th>0.3</th>
<th>1.0</th>
<th>3.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine (n=5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volume</td>
<td></td>
<td>13.0±6.6</td>
<td>6.9±6.2</td>
<td>9.6±0.8</td>
<td>Not tested</td>
</tr>
<tr>
<td>Acid concentration</td>
<td></td>
<td>4.3±2.3</td>
<td>18.7±4.4</td>
<td>53.4±2.9</td>
<td></td>
</tr>
<tr>
<td>Acid output</td>
<td></td>
<td>14.6±7.2</td>
<td>73.4±6.4</td>
<td>97.8±0.5</td>
<td></td>
</tr>
<tr>
<td>Cimetidine (n=8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volume</td>
<td></td>
<td>9.8±1.1</td>
<td>45.2±5.2</td>
<td>91.0±3.2</td>
<td></td>
</tr>
<tr>
<td>Acid concentration tested</td>
<td></td>
<td>9.7±0.7</td>
<td>9.5±2.0</td>
<td>36.7±13.1</td>
<td></td>
</tr>
<tr>
<td>Acid output</td>
<td></td>
<td>9.3±1.3</td>
<td>48.8±5.5</td>
<td>92.5±3.2</td>
<td></td>
</tr>
<tr>
<td>Metiamide (n=8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Volume</td>
<td></td>
<td>21.0±6.0</td>
<td>41.2±5.6</td>
<td>80.7±5.0</td>
<td></td>
</tr>
<tr>
<td>Acid concentration tested</td>
<td></td>
<td>1.2±1.0</td>
<td>4.6±0.8</td>
<td>28.6±8.9</td>
<td></td>
</tr>
<tr>
<td>Acid output</td>
<td></td>
<td>21.0±7.0</td>
<td>43.1±5.7</td>
<td>82.0±5.1</td>
<td></td>
</tr>
</tbody>
</table>

n = number of experimental animals.

Fig. 4  Inhibition of pentagastrin-induced gastric acid secretion after intravenous (A) and oral (B) doses of ranitidine ●, cimetidine ▲, and metiamide □. Values are means ±SE from at least five dogs. The lines shown are calculated lines of best fit; there is no significant difference in slope for the three drugs. Asterisks indicate where a value is significantly different from that achieved with the same dose of cimetidine, at *p<0.05, **p<0.01 (unpaired t test).

Fig. 5  Inhibition of betahanechol-induced gastric acid secretion following intravenous (A) and oral (B) doses of ranitidine ●, cimetidine ▲, and metiamide □. Values are means ±SE from at least five dogs. The lines shown are calculated lines of best fit; there is no significant difference in slope for the three drugs. Asterisks indicate where a value is significantly different from that achieved with the same dose of cimetidine, at *p<0.05, **p<0.01 (unpaired t test).

Effects of a range of doses of ranitidine, cimetidine, and metiamide (Fig. 3) shows that ranitidine is clearly the most potent inhibitor of histamine stimulated gastric acid secretion.

The inhibition of histamine-induced gastric secretion after the three H2-receptor antagonists is mainly attributable to a reduction in volume of secretion but, particularly at higher dose levels, a significant reduction in the concentration of acid could also be detected. This is illustrated in Table 1 by the results obtained after oral doses of the antagonists during histamine-induced gastric secretion.

The dose levels of ranitidine, cimetidine, and metiamide shown to be effective against histamine-induced secretion have also been tested during secretory plateaux obtained with pentagastrin or betahanechol. As shown in Figs 4 and 5 all three
Inhibition of gastric acid secretion in the dog

Table 2  Effect of ranitidine on gastric secretion, gastric mucosal blood flow, and clearance ratio

Table 3  Antisecretory \( ED_{50} \) values and relative potencies (with 95% confidence limits) for ranitidine, cimetidine, and metiamide in the dog

Discussion

Ranitidine is a potent inhibitor of gastric acid secretion in the dog and is qualitatively similar to the established \( H_2 \)-receptor antagonists metiamide and cimetidine. Thus ranitidine is effective in reducing secretion from the Heidenhain pouch of the dog, whether given intravenously or by mouth; and its antisecretory effect is mainly through a reduction in the volume of gastric secretion, with a lesser effect on the concentration of acid secreted. The duration of the antisecretory effect of ranitidine after a single oral dose is as long or longer than that of cimetidine. The antisecretory activity of ranitidine is not due to any limiting action on mucosal blood flow, as the ratio of mucosal blood flow to acid secretion actually rose after administration of ranitidine. Metiamide has also been shown to increase the ratio of mucosal blood flow to acid secretion while reducing acid secretion elicited by either histamine or pentagastrin.\(^9\)

Ranitidine, when given intravenously or orally to the dog, was always significantly more potent than cimetidine as an inhibitor of gastric acid secretion elicited by histamine, pentagastrin, or the choline ester, bethanechol. The potency of ranitidine relative to cimetidine ranged from 4:3 to 9:5, depending on which secretagogue was used. Cimetidine has been reported to be about twice as active as metiamide as an inhibitor of gastric secretion\(^2\), but no direct comparison of their relative potencies in the dog has previously appeared in the literature. In the present study cimetidine was between 1:1 to 2:5 times as active as metiamide, but this difference in potency was not always statistically significant.

In addition to its greater potency, ranitidine also

*Significantly different from cimetidine at \( p < 0.05 \).
differs from cimetidine in its chemical structure. Ranitidine is a substituted aminomethyl furan, whereas metiamide and cimetidine are both based on the imidazole ring structure of histamine itself. Metiamide was withdrawn from clinical use after there had been a few cases of reversible agranulocytosis.11 This toxic effect is probably associated with the presence of a thiourea group in the metiamide molecule, and does not appear to be a problem with cimetidine, a close structural analogue in which thiourea is replaced by cyanoguanidine.12 A low incidence of minor side-effects has been reported for cimetidine13 and, if these are unrelated to H2-receptor blockade, they may not occur with a non-imidazole compound like ranitidine.

Initial reports claimed that the H2-receptor antagonists burimamide and metiamide did not antagonise secretion induced by choline esters in the dog.10,13 However, more recently metiamide and cimetidine have both been described as effective against secretion stimulated by choline esters.8,14 The effectiveness of metiamide as an inhibitor of secretion induced by choline esters in the dog appears to be dependent on the experimental design used.15

In other systems cimetidine, metiamide, and ranitidine have been shown to be selective antagonists of the effects of histamine at H2-receptors but, in the stomach, these antagonists are effective inhibitors of several gastric secretagogues other than histamine. The reason for this paradox is probably that histamine can increase gastric secretion in two ways—firstly, by a direct stimulant action of its own on the parietal cells and, secondly, by potentiating the stimulant actions of gastrin (or pentagastrin) and acetylcholine (or other similar choline esters).16,17 An H2-receptor antagonist can antagonise both the direct effect of histamine and its potentiating action and thus reduces gastric secretion elicited by histamine, choline esters, or gastrin. Consequently, the effectiveness of ranitidine as an inhibitor of gastric secretion elicited by betahexanol, pentagastrin, or histamine is entirely consistent with its known properties as an H2-receptor antagonist.

Ranitidine, as well as inhibiting gastric acid secretion induced by histamine, pentagastrin, and betahexanol in the dog, will also markedly reduce secretion elicited by 2-deoxy-D-glucose or a test meal.18

Ranitidine has recently been shown to be a potent inhibitor of pentagastrin stimulated gastric secretion in patients with duodenal ulceration18 and thus this drug appears to be highly suitable for clinical trial for the treatment of peptic ulceration.

References


18 Daly MJ, Humphray JM, Stables R. Inhibition of gastric acid secretion by the new H2-receptor antagonist ranitidine in the dog with a gastric fistula (abstract). Gut 1979; 20: A914.

Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine, and metiamide.

M J Daly, J M Humphray and R Stables

Gut 1980 21: 408-412
doi: 10.1136/gut.21.5.408

Updated information and services can be found at:
http://gut.bmj.com/content/21/5/408

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
Gastrointestinal hormones (848)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/